At a glance
ClinicalIndex Comparison RecordN/ACompleted· 667 enrolled
Drug / intervention
Cobas HPV DNA Test +1 moredevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Human Papillomavirus Testing Versus Liquid-based Cytology for Non-attendees of Cervical Cancer Screening: Results of a Randomised Controlled Trial
In Brief
A clinical study evaluating Cobas HPV DNA Test and Papanicolau test for Cancer of the Uterine Cervix. Completed, enrolled 667 participants.
Detailed Summary
The purpose of this study is to determine whether human-papillomavirus (HPV) self-sampling can be used as a primary screening test for unscreened women.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCancer of the Uterine Cervix
Countries--
Collaborators--
Timeline
N/ACompletedFinished
201220132014201520162017201820192020202120222023202420252026
Enrollment StartSep 2011
Primary CompletionJan 2016
First PostedMar 2016
TodayJul 2026
First PostedMar 3, 2016
Enrollment StartSep 1, 2011
Primary CompletionJan 1, 2016
TodayJul 2, 2026
Enrollment to primary: 4.3 yearsPosted 10.3 years ago
Interventions
Cobas HPV DNA Testdevice
Women will receive a home-sent sample for HPV self-testing
Papanicolau testother
Women will be invited to come in for a physician-performed Pap test